NCT05859074

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Recruiting now Phase 1 Last updated 3 December 2025

What this trial tests

Phase 1 trial testing MQ719 in Cutaneous Squamous Cell Carcinoma in 56 participants. Currently enrolling.

Timeline

4 May 2023

Primary endpoint
4 May 2028

4 May 2028

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	56
Start date	4 May 2023
Primary completion	4 May 2028
Estimated completion	4 May 2028
Sites	7 locations across United States

Drugs / interventions tested

• MQ719 — full drug profile →
• Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

• Cutaneous Squamous Cell Carcinoma — all drugs for Cutaneous Squamous Cell Carcinoma →
• SCC - Squamous Cell Carcinoma — all drugs for SCC - Squamous Cell Carcinoma →
• Basal Cell Carcinoma — all drugs for Basal Cell Carcinoma →
• BCC — all drugs for BCC →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Cutaneous Squamous Cell Carcinoma or SCC - Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation?
   Yiong CS, Lin TP, Lim VY, Toh TB, et al · · 2023 · cited 26× · PMID 37612756 · DOI 10.1186/s40364-023-00513-5
2. Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages.
   Shen Z, Liu X, Fan G, Na J, et al · · 2023 · cited 24× · PMID 37993941 · DOI 10.1186/s12967-023-04709-z
3. Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.
   Skalickova M, Hadrava Vanova K, Uher O, Leischner Fialova J, et al · · 2024 · cited 10× · PMID 39850897 · DOI 10.3389/fimmu.2024.1479483
4. The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review.
   Spirito F, Nocini R, Mori G, Albanese M, et al · · 2024 · cited 7× · PMID 39684701 · DOI 10.3390/ijms252312990
5. Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update.
   Gambichler T, Schrama D, Käpynen R, Weyer-Fahlbusch SS, et al · · 2024 · cited 7× · PMID 38793784 · DOI 10.3390/vaccines12050533
6. Therapeutic Advances in Advanced Basal Cell Carcinoma.
   Alkassis S, Shatta M, Wong DJ. · · 2024 · cited 4× · PMID 39272933 · DOI 10.3390/cancers16173075
7. Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.
   Lessans S, O'Connell KA, Choe J. · · 2024 · cited 4× · PMID 38954315 · DOI 10.1007/s11912-024-01570-1
8. Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review.
   Garg A, Rao R, Tejawinata F, Shamita GAN, et al · · 2025 · cited 2× · PMID 40733704 · DOI 10.3390/vaccines13070727